e.g. mhealth
Search Results (1 to 1 of 1 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 1 JMIR Cancer
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials
This approach has been acceptable for cytotoxic chemotherapy drugs due to their steep dose-response relationships, their limited drug target specificity, and the willingness of patients to trade off substantial toxicity to treat serious, life-threatening diseases [2]. However, it may lead to the recommendation of higher doses and a suboptimal tolerability profile when used in dose finding for modern, more targeted oncology drugs such as kinase inhibitors and monoclonal antibodies (Figure 2).
JMIR Cancer 2025;11:e64611
Download Citation: END BibTex RIS